UTHR
United Therapeutics CorporationNASDAQ
Healthcare • Drug Manufacturers - Specialty & Generic
Factor tilt: Large-Cap Blend
$562.02-0.65%
Close Nov 6, 2026
- Market cap
- $23.86B
- 1 month
- +5.5%
- 3 months
- +6.1%
- 1 year
- +25.6%
- 52-week range
- $448.91$608.49
- Dividend
- No dividends on record
- Next-quarter EPS estimate
- $6.04Quarter to Sep 30, 2026 · 14 analysts · revenue $781.14M · -6.5% in 30d
- Short interest
- 6.3% of float2.5M shares · settled Oct 15, 2026 · -31.7% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $3.15B
- Net income
- $1.31B
- Free cash flow
- $1.09B
- Book value
- $6.4B
- Total debt
- —
- P/E
- 18.2×
- Price / sales
- 7.6×
- Price / book
- 3.7×
- FCF yield
- +4.6%
- Net margin
- +41.6%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About United Therapeutics Corporation
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
Read more
It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
- Website
- unither.com
- Headquarters
- Silver Spring, MD, United States
- Employees
- 1,400
- Listed
- Jun 17, 1999
- Fiscal year ends
- December
Company profile from EODHD, stored Oct 23, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 5, 2026 | $783.3M | -1.9% | 87.3% | $330.8M | $333.0M |
| Mar 2026filed May 6, 2026 | $781.5M | -1.6% | 82.9% | $325.8M | $274.9M |
| Dec 2025filed Feb 25, 2026 | $790.2M | +7.4% | 86.9% | $357.5M | $364.3M |
| Sep 2025filed Oct 29, 2025 | $799.5M | +6.8% | 87.4% | $389.3M | $338.7M |
| Jun 2025filed Jul 30, 2025 | $798.6M | +11.7% | 89.0% | $364.5M | $309.5M |
| Mar 2025filed Apr 30, 2025 | $794.4M | +17.2% | 88.4% | $382.8M | $322.2M |
| Dec 2024filed Feb 26, 2025 | $735.9M | +19.7% | 89.7% | $357.7M | $301.3M |
| Sep 2024filed Oct 30, 2024 | $748.9M | +22.9% | 88.9% | $343.1M | $309.1M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Feb 25, 2026 | $3.2B | +10.6% | 87.9% | $1.5B | $1.3B |
| Dec 2024filed Feb 26, 2025 | $2.9B | +23.6% | 89.2% | $1.4B | $1.2B |
| Dec 2023filed Feb 21, 2024 | $2.3B | +20.2% | 88.9% | $1.2B | $984.8M |
| Dec 2022filed Feb 22, 2023 | $1.9B | +14.9% | 92.4% | $979.7M | $727.3M |
| Dec 2021filed Feb 24, 2022 | $1.7B | +13.6% | 92.7% | $555.9M | $475.8M |
| Dec 2020filed Feb 24, 2021 | $1.5B | +2.4% | 92.7% | $593.6M | $514.8M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched UTHR. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
2,457,723 shares short
-1,139,225 shares (-31.7%) vs Sep 30, 2026
6.3% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
3,596,948 shares short
+796,478 shares (+28.4%) vs Sep 15, 2026
9.2% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
2,800,470 shares short
+740,785 shares (+36%) vs Aug 31, 2026
7.2% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
2,059,685 shares short
-52,682 shares (-2.5%) vs Aug 14, 2026
5.3% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
2,112,367 shares short
-210,234 shares (-9.1%) vs Jul 31, 2026
5.4% of the stored float. Published Aug 25, 2026.
Settlement Jul 31, 2026
2,322,601 shares short
+233,853 shares (+11.2%) vs Jul 15, 2026
6% of the stored float. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind UTHR’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
2 for 1 · forward split
Effective Sep 23, 2009
Each 1 pre-split share becomes 2 post-split shares.
Source: EODHD
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if UTHR is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
139 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Nov 5, 2026
Smart-money 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: bearish
Last trade: sell 2 days ago
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 7
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
889 filers reported a long position in UTHR for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
46.5%
of the 41.7M shares 13-F filers reported
Moves vs Q1 2026
2 added6 trimmed
2 not comparable
Net shares held
-6.4%
across the 8 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | $2.9B · 5.3M shares | 5.3M | -1.9% |
| 2 | Avoro Capital Advisors LLC | $1.5B · 2.8M shares | 2.8M | +5.6% |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | $1B · 1.9M shares | 1.9M | -4.2% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | $1B · 1.9M shares | 1.9M | -2% |
| 5 | STATE STREET CORP | $1B · 1.9M shares | 1.9M | +2.9% |
| 6 | RENAISSANCE TECHNOLOGIES LLC | $925.8M · 1.7M shares | 1.7M | -4.4% |
| 7 | WELLINGTON MANAGEMENT GROUP LLP | $747.2M · 1.4M shares | 1.4M | -39.1% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | $538.9M · 996.6K shares | 996.6K | -19.2% |
| 9 | Jupiter Topco LLC | $450.1M · 831.1K shares | 831.1K | — |
| 10 | NORGES BANK | $376.4M · 694.8K shares | 694.8K | — |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of UTHR file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Nov 4, 2026 | ROTHBLATT MARTINE A13G · passive · amended | 4%under 5% |
| Aug 13, 2026 | WELLINGTON MANAGEMENT GROUP LLP13G · passive · amended | 3.2%under 5% |
| Apr 30, 2026 | VANGUARD CAPITAL MANAGEMENT LLC13G · passive | 5.19% |
| Mar 27, 2026 | VANGUARD GROUP INC13G · passive · amended | 0%under 5% |
Get the Full Analysis for UTHR
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.